CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 3 enrolled
Drug / intervention
Naltrexonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01873729
NCT01873729Phase 4Completed
CompareCT.gov

An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

Massachusetts General Hospital·interventional·Posted Jun 10, 2013·Updated Jan 13, 2017

In Brief

A Phase 4 clinical trial evaluating Naltrexone for Attention Deficit Hyperactivity Disorder. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa opioid receptor antagonist, it increases dopamine in the brain. We predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults with ADHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 10, 2013
Enrollment StartNov 1, 2013
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.1 years ago

Interventions

Naltrexonedrug

Adults with ADHD